Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis

Next Previous
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LATTICE-UC
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 25 Apr 2023 Status changed from active, no longer recruiting to completed.
  • 26 Oct 2022 Results of post-hoc subanalysis evaluating the effect of deucravacitinib in biologic-exposed patients with moderately to severely active UC,presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
  • 11 Oct 2022 Results of post-hoc analysis in biologic-exposed patients assessing improvements at week 12 in clinical remission; clinical response; endoscopic improvement; and change from baseline in symptomatic, presented at the 30th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top